IPOs

Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Endpoints
IPOs
SPAC
Finch Therapeutics
microbiome
Connect Biopharma
Insil Bio
Transcode Therapeutics
Flag link:
With Novavax vaccine deal under its belt, SK Bioscience plots out March IPO on the Korean exchange
With Novavax vaccine deal under its belt, SK Bioscience plots out March IPO on the Korean exchange
Endpoints
SK Bioscience
IPOs
South Korea
vaccines
COVID-19
Novavax
Flag link:
After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard
After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard
Endpoints
IPOs
Prometheus Biosciences
Longboard Pharmaceuticals
Gain Therapeutics
Flag link:
A pair of biotechs prepares to hit Nasdaq, as total 2021 IPO raise quickly approaches $3B
A pair of biotechs prepares to hit Nasdaq, as total 2021 IPO raise quickly approaches $3B
Endpoints
IPOs
Adagene
Decibel Therapeutics
NexImmune
Protagenic
Flag link:
Biotech flotations offer venture funds an accelerating exit
Biotech flotations offer venture funds an accelerating exit
EP Vantage
biotech
IPOs
startups
M&A
Flag link:
Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers
Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers
Endpoints
Nautilus Biotechnology
NASDAQ
SPAC
IPOs
reverse merger
M&A
Arya Sciences
Flag link:
Life Sciences Companies Ringing the Nasdaq Bell this Week
Life Sciences Companies Ringing the Nasdaq Bell this Week
BioSpace
IPOs
NASDAQ
Sana Biotechnology
Sensei Biotherapeutics
Landos Biopharma
Aspira Women's Health
Equillium
Flag link:
Cell therapy biotech Sana Biotechnology prices further upsized IPO at $25, above the upwardly revised range
Cell therapy biotech Sana Biotechnology prices further upsized IPO at $25, above the upwardly revised range
Renaissance Capital
IPOs
Sana Biotechnology
cell therapy
Flag link:
Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks
Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks
Fierce Biotech
Immunocore
IPOs
kickbacks
Immatics
Flag link:
IPO tracker: 2021 gets started with a flurry of new offerings
IPO tracker: 2021 gets started with a flurry of new offerings
Endpoints
IPOs
Sana Biotechnology
Sensei Biotherapeutics
Bolt Biotherapeutics
Immunocore
Terns Pharmaceuticals
Pharvaris
Vor Biopharma
Adagene
NexImmune
Biophytis
Gracell Biotechnologies
Cullinan Oncology
Flag link:
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
Fierce Biotech
NexImmune
Gilead Sciences
Kite Pharma
IPOs
Flag link:
Sana Bio's $150 Million IPO Expected to Provide Market Valuation of $10 Billion
Sana Bio's $150 Million IPO Expected to Provide Market Valuation of $10 Billion
BioSpace
Sana Biotechnology
IPOs
Flag link:
Astounding success greets newly public device makers
Astounding success greets newly public device makers
EP Vantage
IPOs
devices
Medtech
Sotera Health
Outset Medical
Genetron Holdings
Burning Rock Biotech
Pulmonx
Acutus Medical
Nano-X Imaging
Eargo
Implantica
Inari Medical
Flag link:
Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?
Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?
BioSpace
Landos Biopharma
IPOs
Flag link:
Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO
Emerging Seattle-Based Sana Biotechnology Seeks to Raise $150 Million IPO
BioSpace
IPOs
Sana Biotechnology
Flag link:
After a big year, biotech flotations have much to do
After a big year, biotech flotations have much to do
EP Vantage
IPOs
biotech
Flag link:
2021 forecast: In spite of COVID-19—and partly because of it—biotech IPOs have a record year
2021 forecast: In spite of COVID-19—and partly because of it—biotech IPOs have a record year
Fierce Biotech
biotech
pandemic
IPOs
COVID-19
Flag link:
The biotech IPO train keeps chugging, as Virios prices $30M public debut
The biotech IPO train keeps chugging, as Virios prices $30M public debut
Endpoints
Virios Therapeutics
IPOs
Flag link:
AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO
AbbVie's Covid-19 antibody partner wraps $221M Hong Kong IPO
Endpoints
AbbVie
Harbour BioMed
IPOs
Hong Kong
Flag link:
BioAtla heads for Nasdaq on Wednesday following $189M IPO, going public with its pH-detecting cancer treatments
BioAtla heads for Nasdaq on Wednesday following $189M IPO, going public with its pH-detecting cancer treatments
Endpoints
BioAtla
IPOs
NASDAQ
Flag link:

Pages